(IIPR) Innovative Industrial - Ratings and Ratios
Industrial Properties, Life Science Real Estate, Medical-Use Cannabis Facilities, Sale-Leaseback Transactions
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 15.35% |
| Yield on Cost 5y | 7.10% |
| Yield CAGR 5y | 13.89% |
| Payout Consistency | 100.0% |
| Payout Ratio | 1.8% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 37.9% |
| Value at Risk 5%th | 57.8% |
| Relative Tail Risk | -7.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.31 |
| Alpha | -59.98 |
| CAGR/Max DD | -0.29 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.206 |
| Beta | 0.734 |
| Beta Downside | 0.621 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.92% |
| Mean DD | 30.69% |
| Median DD | 31.91% |
Description: IIPR Innovative Industrial November 14, 2025
Innovative Industrial Properties, Inc. (NYSE:IIPR) is a publicly traded REIT that acquires, owns, and manages specialized industrial and life-science properties, primarily leasing to federally regulated cannabis cultivators.
Key operating metrics that investors watch include a ~96% occupancy rate across its portfolio, a 2023 funds-from-operations (FFO) growth of roughly 12% year-over-year, and a leverage ratio near 5.2× net debt to EBITDA. The REIT’s performance is closely tied to macro-drivers such as the pace of U.S. cannabis legalization, interest-rate sensitivity typical of REITs, and broader industrial-real-estate demand for high-spec facilities.
For a deeper, data-driven look at IIPR’s valuation multiples and peer comparison, you might explore the analytics available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (126.4m TTM) > 0 and > 6% of Revenue (6% = 16.6m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -1.50pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -5.73% (prev 9.35%; Δ -15.08pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 206.3m > Net Income 126.4m (YES >=105%, WARN >=100%) |
| Net Debt (303.6m) to EBITDA (216.8m) ratio: 1.40 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.91 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (28.3m) change vs 12m ago -0.97% (target <= -2.0% for YES) |
| Gross Margin 89.20% (prev 90.98%; Δ -1.77pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 11.66% (prev 12.98%; Δ -1.32pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.62 (EBITDA TTM 216.8m / Interest Expense TTM 16.6m) >= 6 (WARN >= 3) |
Altman Z'' -0.68
| (A) -0.01 = (Total Current Assets 159.7m - Total Current Liabilities 175.5m) / Total Assets 2.34b |
| (B) -0.12 = Retained Earnings (Balance) -289.9m / Total Assets 2.34b |
| (C) 0.06 = EBIT TTM 143.0m / Avg Total Assets 2.37b |
| (D) -0.61 = Book Value of Equity -289.9m / Total Liabilities 474.6m |
| Total Rating: -0.68 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 65.42
| 1. Piotroski 5.50pt |
| 2. FCF Yield 11.45% |
| 3. FCF Margin 68.43% |
| 4. Debt/Equity 0.18 |
| 5. Debt/Ebitda 1.40 |
| 6. ROIC - WACC (= -0.57)% |
| 7. RoE 6.65% |
| 8. Rev. Trend 21.17% |
| 9. EPS Trend -52.49% |
What is the price of IIPR shares?
Over the past week, the price has changed by +7.89%, over one month by -6.80%, over three months by -6.64% and over the past year by -48.45%.
Is IIPR a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 2
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the IIPR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 57.3 | 15.6% |
| Analysts Target Price | 57.3 | 15.6% |
| ValueRay Target Price | 50 | 0.9% |
IIPR Fundamental Data Overview November 25, 2025
P/E Trailing = 11.3593
P/E Forward = 11.274
P/S = 4.8779
P/B = 0.7396
Beta = 1.52
Revenue TTM = 276.0m USD
EBIT TTM = 143.0m USD
EBITDA TTM = 216.8m USD
Long Term Debt = 290.2m USD (from longTermDebt, last quarter)
Short Term Debt = 50.0m USD (from shortTermDebt, last quarter)
Debt = 340.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 303.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.65b USD (1.35b + Debt 340.2m - CCE 36.7m)
Interest Coverage Ratio = 8.62 (Ebit TTM 143.0m / Interest Expense TTM 16.6m)
FCF Yield = 11.45% (FCF TTM 188.9m / Enterprise Value 1.65b)
FCF Margin = 68.43% (FCF TTM 188.9m / Revenue TTM 276.0m)
Net Margin = 45.80% (Net Income TTM 126.4m / Revenue TTM 276.0m)
Gross Margin = 89.20% ((Revenue TTM 276.0m - Cost of Revenue TTM 29.8m) / Revenue TTM)
Gross Margin QoQ = 87.71% (prev 89.08%)
Tobins Q-Ratio = 0.71 (Enterprise Value 1.65b / Total Assets 2.34b)
Interest Expense / Debt = 1.33% (Interest Expense 4.53m / Debt 340.2m)
Taxrate = -1.12% (negative due to tax credits) (-1.80m / 161.7m)
NOPAT = 144.6m (EBIT 143.0m * (1 - -1.12%)) [negative tax rate / tax credits]
Current Ratio = 0.91 (Total Current Assets 159.7m / Total Current Liabilities 175.5m)
Debt / Equity = 0.18 (Debt 340.2m / totalStockholderEquity, last quarter 1.86b)
Debt / EBITDA = 1.40 (Net Debt 303.6m / EBITDA 216.8m)
Debt / FCF = 1.61 (Net Debt 303.6m / FCF TTM 188.9m)
Total Stockholder Equity = 1.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.41% (Net Income 126.4m / Total Assets 2.34b)
RoE = 6.65% (Net Income TTM 126.4m / Total Stockholder Equity 1.90b)
RoCE = 6.53% (EBIT 143.0m / Capital Employed (Equity 1.90b + L.T.Debt 290.2m))
RoIC = 6.66% (NOPAT 144.6m / Invested Capital 2.17b)
WACC = 7.23% (E(1.35b)/V(1.69b) * Re(8.72%) + D(340.2m)/V(1.69b) * Rd(1.33%) * (1-Tc(-0.01)))
Discount Rate = 8.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.04%
[DCF Debug] Terminal Value 75.77% ; FCFE base≈205.2m ; Y1≈204.0m ; Y5≈214.1m
Fair Price DCF = 119.5 (DCF Value 3.35b / Shares Outstanding 28.0m; 5y FCF grow -1.24% → 3.0% )
EPS Correlation: -52.49 | EPS CAGR: -4.21% | SUE: 1.05 | # QB: 1
Revenue Correlation: 21.17 | Revenue CAGR: 2.51% | SUE: 0.52 | # QB: 0
Additional Sources for IIPR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle